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Effects of tuberculosis and HIV infection on whole-body protein
metabolism during feeding, measured by the [15N]glycine method1–3
Nicholas I Paton,Yau-Ming Ng, Cynthia BE Chee, Chandarika Persaud, and Alan A Jackson
ABSTRACT
Background: Tuberculosis (TB) and HIV infection are wasting
diseases that frequently occur together and have severe conse-
quences on nutritional status.
Objective: The objective was to determine the effects of TB and
HIV, separately and together, on protein metabolism.
Design: Protein metabolism was determined in the fed state in 11
healthy control subjects, in 10 patients with HIV infection with-
out TB or other active infection (HIV group), in 10 patients with
active TB without HIV infection (TB group), and in 8 patients
with HIV infection and active TB (HIVTB group) with the use of
oral [15N]glycine and measurement of enrichment in urinary urea
and ammonia.
Results: Whole-body protein flux and degradation were lower in
the HIV group than in the control group (mean flux: 3.53 ± 0.40
compared with 4.75 ± 0.97 g·kg lean body mass 1·12 h 1; P= 0.002).
Protein flux, synthesis, and degradation were not significantly dif-
ferent between the control group and the TB and HIVTB groups.
Net protein balance was strongly anabolic in the control, HIV, and
TB groups but was neutral in the HIVTB group (P < 0.001 for
comparison between groups).
Conclusions: HIV infection was associated with a significant
down-regulation of whole-body protein flux. TB alone was not
associated with abnormal protein metabolism, but net anabolism
in the fed state was impaired in the HIVTB group. Am J Clin
Nutr 2003;78:319–25.
KEY WORDS HIV, tuberculosis, infection, protein metabolism,
glycine, wasting
INTRODUCTION
Chronic infections such as HIV and tuberculosis (TB) are often
associated with a deterioration in nutritional status and sometimes
profound wasting. In many developing countries, TB is the most
frequent opportunistic infection in patients with HIV infection,
and coinfected patients appear to be at much greater risk of pro-
found wasting. Postmortem examination of persons who died from
slim disease suggested that infection with TB exacerbates the
wasting process of HIV-infected patients in Africa (1). Wasting
usually reflects the loss of fat mass and body cell mass, and signi-
ficant tissue loss can persist for months after the introduction of
effective therapy for TB (2). Mortality is increased in HIV (3–5)
and in TB (6, 7) patients who have significant wasting. One impor-
tant question is whether nutritional intervention is effective in pre-
venting or correcting wasting, thereby leading to an improved
prognosis and greater efficacy of antiinfective drugs.
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For any infection there is a complex interaction between the
host response and the virulence of the organism, which modulates
the overall metabolic response and the degree and pattern of tis-
sue loss. In patients with HIV infection and TB, a reduction in
appetite—which leads to decreases in energy, protein, and nutri-
ent intakes—may interact with increased losses and altered metab-
olism as part of the inflammatory and immune responses (2, 8, 9).
A clear understanding of the underlying metabolic changes may
help to ensure effective nutritional intervention in wasted patients.
In the presence of ongoing infection, it is possible that supple-
mental feeding will increase fat mass but not lean tissue mass, a
change that is likely to be of little clinical benefit (10). Clinically
stable patients with HIV appear to have a normal response to feed-
ing (11), although the response appears blunted in those with an
acute opportunistic infection (12). Patients with TB may have
some attenuation of the protein anabolic response to food (11). No
study has compared protein metabolism between patients with
HIV infection and TB with the same experimental methods or has
measured the effects of the co-occurrence of the 2 infections in
the same patient.
We therefore investigated the effects of HIV and TB infections,
both independently and together, on protein metabolism. Our
hypothesis was that TB would be associated with reduced net
anabolism during feeding and that this would be further impaired
in patients coinfected with TB and HIV.
SUBJECTS AND METHODS
Patients
The study was conducted at the Communicable Disease Cen-
tre, Tan Tock Seng Hospital, Singapore, between October 1999
and June 2000. Male patients aged 18–60 y were recruited from 4
clinical groups according to the speciﬁc inclusion criteria described
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 320 PATON ET AL
below. We excluded subjects from all groups if they had type 1
diabetes, diarrhea (defined as >3 loose stools/d at any time during
the previous week), symptoms of an upper respiratory tract infec-
tion, or clinically apparent jaundice.
Subjects in the control group were healthy members of hospi-
tal staff who were considered to be at low risk of HIV infection or
healthy blood donors who were receiving counseling for asymp-
tomatic hepatitis B virus infection. (These subjects were negative
for hepatitis B e antigen and HIV antibodies and had normal liver
function.) Patients with HIV infection only (HIV group) were
required to have confirmed HIV infection (by enzyme-linked
immunosorbent assay and Western Blot analysis) and to be free
of opportunistic infection for ≥ 1 mo before the study began.
Patients infected with tuberculosis only (TB group) were required
to have a clinical diagnosis of tuberculosis, to have been receiving
antituberculosis chemotherapy for <2 wk at the time of the study,
and to have a negative result from an HIV antibody test or to be
free of HIV risk factors, which was ascertained by specific ques-
tioning by the primary physician and study staff. Patients infected
with both HIV and TB (HIVTB group) were required to have con-
firmed HIV infection, to have a clinical diagnosis of TB, to have
been receiving antituberculosis therapy for <2 wk at the time of
study, and to be free of other HIV-related opportunistic infections
for ≥1 mo before the study began. The protocol was explained to
the subjects before participation, and all subjects gave written
informed consent. The study was approved by the Ethics Com-
mittee of Tan Tock Seng Hospital.
Methods
Protein metabolism
Whole-body protein metabolism was measured by using the
[15N]glycine end product method as previously reported (13, 14)
and as outlined below. Subjects were studied in the morning after
an overnight fast, during which time only water was permitted. A
single oral dose of 100 mg [15N]glycine (99% atoms excess; Icon
Services Inc, Summit, NJ) was dissolved in 100 mL sterile water
and administered at 0800. Subsequently, at 3-h intervals thereafter
until the completion of the 12-h protocol, subjects were given
drinks containing a powdered nutritional supplement (2 g/kg body
wt, Ensure; Ross Laboratories, Columbus, OH) made up in ster-
ile water to a volume of  200 mL. Subjects were allowed to drink
additional water as desired during the 12-h study protocol but no
other drinks or food orally. This regimen was designed to provide
the daily food requirement over the 12-h period. The total protein
intake was equivalent to 1.27 g/kg body wt, and the total energy
intake was 151 kJ/kg body wt.
A blood sample (20 mL) was collected into heparin-containing
tubes before and 12 h after the administration of [15N]glycine.
The plasma was separated and stored at  70 C until analyzed.
A urine sample was collected into a 200-mL container with 0.1 mL
chlorhexidine and 1.5 mL of 7 mol HCl/L before the adminis-
tration of [15N]glycine. After the administration of the isotope,
urine was collected continuously for 12 h into a container with
2 mL chlorhexidine and 20 mL of 7 mol HCl/L. The total vol-
ume of urine was measured, and aliquots were stored at  30 C
until analyzed.
The enrichments of urea nitrogen and ammonia nitrogen in
urine and the enrichment of urea nitrogen in blood were measured
as previously described (14). The rate of nitrogen flux was calcu-
lated by using the following equation (13):
Q=d     Ex/ex  (1)
where Q is the rate of nitrogen flux (grams of nitrogen over 12 h),
d is the amount of isotope administered (grams of 15N), Ex is the
amount of ammonia or urea excreted (grams of nitrogen over 12 h),
and ex is the amount of isotope excreted in urine as ammonia or
the amount of isotope excreted in urine as urea and retained in the
urea pool of the body (grams of 15N over 12 h). Rates of flux were
estimated on the basis of the recovery of label in either ammonia
or urea as the end product and also by using the arithmetic aver-
age for the 2 end products.A factor of 6.25 was used to convert the
flux values from grams of nitrogen to grams of protein.
Whole-body rates of protein synthesis and degradation were
calculated by using the following equation:
Q=  E t + S = I + D (2)
where Et is the corrected rate of protein excretion (calculated from
total nitrogen in urine), S is the rate of protein synthesis, I is the
rate of protein intake from the diet, and D is the rate of whole-
body protein degradation (13). The calculation assumes that 100%
of the administered food is absorbed. Rates were expressed as
absolute rates of protein turnover, rates relative to body weight,
and rates relative to total lean body mass.
Dietary, anthropometric, body-composition, and laboratory
measurements
The habitual food consumption of all subjects was estimated
by using a 3-d dietary recall method. Commercial computer soft-
ware (NUTRITIONIST IV; The Hearst Corporation, San Bruno,
CA) was used for the analysis.
Height was measured to the nearest 1 mm with a portable sta-
diometer, and body weight was measured to the nearest 0.1 kg
with the use of calibrated electronic scales. Body mass index was
calculated as weight (in kg) divided by the square of the height
(in m). Body composition was measured by dual-energy X-ray
absorptiometry with a Hologic QDR 2000+ scanner with software
version 5.71 (Hologic Inc, Bedford, MA). The scan was performed
between 0900 and 1000 on the morning of the study day. The sub-
jects wore light indoor clothing, and the measurements were made
in the fed state. Appendicular lean tissue mass was obtained from
the sum of lean tissue in the arms and legs, and visceral lean tis-
sue mass was considered to be the trunk lean tissue measurement
(ie, the remaining lean tissue, other than from the head region).
Blood was also collected on the study day for measurement of
the erythrocyte sedimentation rate and C-reactive protein and
albumin concentrations with the use of standard laboratory meth-
ods. Case sheets of patients were reviewed for details of HIV and
TB disease and treatment.
Statistical analysis
A comparison of variables between the 4 clinical disease
groups was made by analysis of variance with a post hoc
Scheffe’s test. Pearson’s test was used to assess the correlation
between flux measurements and regional body composition. All
statistical tests were two sided, and a P value <0.05 was regarded
as significant. The analysis was performed by using SPSS version
9.0 (SPSS Inc, Chicago).
RESULTS
A total of 45 subjects were studied. Of these, 4 failed to com-
plete the protocol adequately (incomplete urine collection and
 
a
t
 
U
n
i
v
 
o
f
 
S
o
u
t
h
a
m
p
t
o
n
 
W
e
s
s
e
x
 
M
e
d
i
c
a
l
 
L
i
b
r
a
r
y
 
o
n
 
S
e
p
t
e
m
b
e
r
 
1
2
,
 
2
0
0
7
 
w
w
w
.
a
j
c
n
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 PROTEIN METABOLISM IN TUBERCULOSIS AND HIV 321
TABLE 1
Comparison of anthropometric, body-composition, and laboratory variables between the 4 groups of subjects1
Group
Control (n = 11) HIV (n = 10) TB (n = 10) HIVTB (n =8 ) P2
Age (y) 40.8 ± 8.4 37.1 ± 4.1 40.3 ± 9.9 36.3 ± 4.8 0.45
Height (cm) 167.4 ± 4.7 169.6 ± 5.9 167.9 ± 4.6 168.6 ± 8.5 0.85
Weight (kg) 61.2 ± 8.9 63.0 ± 3.3 50.8 ± 6.23,4 51.0 ± 7.63,4 <0.001
BMI (kg/m2) 21.8 ± 3.0 22.0 ± 1.5 18.0 ± 2.33,4 17.9 ± 2.33,4 <0.001
Fat (kg) 13.7 ± 5.4 11.3 ± 2.9 7.4 ± 3.53 7.0 ± 3.73 0.002
Lean tissue mass (kg) 44.1 ± 4.6 47.5 ± 3.9 40.1 ± 2.84 41.0 ± 5.34 0.001
Appendicular lean tissue mass (kg) 18.7 ± 2.0 19.6 ± 18.7 15.7 ± 2.03,4 15.8 ± 2.43,4 <0.001
Visceral lean tissue mass (kg) 22.1 ± 2.2 24.5 ± 2.0 21.2 ± 1.34 22.1 ± 2.8 0.009
Visceral:appendicular lean tissue mass 1.19 ± 0.06 1.25 ± 0.06 1.36 ± 0.153 1.41 ± 0.103,4 <0.001
Hemoglobin (g/dL) 14.6 ± 1.3 15.4 ± 1.1 13.1 ± 1.64 10.2 ± 1.73–5 <0.001
White cells (  109/L) 6.39 ± 1.15 5.07 ± 1.99 9.66 ± 5.754 4.54 ± 2.475 0.009
Lymphocytes (%) 32.0 ± 7.3 30.2 ± 5.7 20.1 ± 7.63,4 21.2 ± 8.93 0.001
Total protein (g/L) 76.4 ± 4.5 79.3 ± 3.3 79.8 ± 4.4 76.1 ± 12.1 0.71
Albumin (g/L) 44.9 ± 1.4 44.4 ± 2.3 38.5 ± 4.03,4 29.6 ± 3.53–5 <0.001
Globulin (g/L) 30.9 ± 3.9 34.9 ± 4.5 41.3 ± 4.83 46.5 ± 9.03,4 <0.001
ESR (mm/h) 7.6 ± 9.1 8.9 ± 11.8 81.8 ± 39.03,4 79.7 ± 36.23,4 <0.001
CRP (mg/L) 5.7 ± 4.8 3.9 ± 0.9 51.8 ± 45.43,4 23.4 ± 14.3 <0.001
1x – ± SD. Body composition was measured by dual-energy X-ray absorptiometry. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. TB,
tuberculosis; HIVTB, coinfection with HIV and TB.
2ANOVA with post hoc Scheffe’s test.
3Signiﬁcantly different from the control group, P < 0.05.
4Signiﬁcantly different from the HIV group, P < 0.05.
5Signiﬁcantly different from the TB group, P < 0.05.
noncompliance with the feeding schedule) and 2 others were
excluded from the analysis because of later evidence that con-
tradicted the initial clinical diagnosis of TB. Thus, 39 subjects
were available for the analysis: 11 control subjects (8 hospital
staff and 3 carriers of hepatitis B), 10 in the HIV group, 10 in
the TB group, and 8 in the HIVTB group. The HIV group had a
mean CD4+ count of 259 cells/mm3 and a mean HIV viral load
of 4.4 log10 copies/mL; 4 patients in this group were receiving
antiretroviral treatment at the time of the study (dual or single
nucleosides only). In the TB group, all subjects had pulmonary
disease (one had lymphadenopathy also) and all but one (in
whom the diagnosis was confirmed by clinical and radiologic
response to antituberculosis treatment) had Mycobacterium
tuberculosis cultured in their sputum. The mean duration of TB
treatment at the time of the study was 6 d (range: 1–12 d), and
none of the patients had taken corticosteroids. The HIVTB group
had a mean CD4+ cell count of 40 cells/mm3, and a mean HIV
viral load of 5.3 log10 copies/mL; only 1 patient was receiving
antiretroviral treatment (dual nucleosides) at the time of the
study. All subjects in this group had disseminated tuberculosis
(including pulmonary disease in all but one) involving a variety
of sites (lymph nodes, liver, spleen, prostate, and blood) and all
had M. tuberculosis cultured from one or more sites. The mean
duration of TB treatment at the time of the study was 9 d (range:
5–13 d), and one patient had taken adjunctive corticosteroids. Of
the 39 subjects, 30 (77%) were Chinese, and the racial distribu-
tion (Chinese compared with other Asian races) was not signifi-
cantly different between the 4 groups.
The characteristics of the groups of subjects are shown in
Table 1. There was no difference in age or height between the
groups. Whereas no significant differences in weight or body mass
index were observed between the HIV and the control groups,
both the TB and HIVTB groups were severely wasted. This
wasting was characterized by a significant loss of fat mass and
appendicular lean tissue mass; visceral lean tissue mass was rel-
atively preserved. The HIV group had hematologic values that
did not differ significantly from those of the control group, but
hemoglobin concentrations and lymphocyte counts (%) were
significantly lower in the TB and HIVTB groups than in the con-
trol and HIV groups. The TB and HIVTB groups had clear evi-
dence of ongoing inflammation on the basis of elevated erythro-
cyte sedimentation rates and C-reactive protein concentrations,
which were not evident in the HIV and control groups. Total
plasma proteins were not significantly different between the 4
groups, but plasma albumin was significantly lower and plasma
globulin was significantly higher in the TB and HIVTB groups
than in the control and HIV groups.
The habitual energy and protein intakes of the subjects are
shown in Table 2. No significant difference in total energy con-
sumption or energy consumption relative to body weight was
observed between the 4 groups. The HIV group had a significantly
higher consumption of protein, and the proportion of total energy
derived from protein was greater in this group.
The results of the protein metabolism measurements are given
in Table 3. Estimates of nitrogen flux based on the excretion of
isotope in either urea or ammonia are shown, as are values of
protein flux derived from the average of the end products.
Absolute values and values normalized by body weight or lean
body mass are all shown. The pattern and direction of differ-
ences between the patient groups was similar regardless of the
end product used for the estimate of flux or of the method of
expression, although these differences were not significant when
calculations were based on the ammonia end product alone. Pro-
tein flux calculated from the average end product was 26%
lower and the rate of protein degradation was 35% lower in the
HIV group than in the control group, but protein synthesis and
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TABLE 3
Comparison of protein metabolism measurements between the 4 groups1
Group
Control (n = 11) HIV (n = 10) TB (n = 10) HIVTB (n =8 ) P2
Protein ﬂux
Qu (g N/12 h) 26.3 ± 4.0 22.3 ± 4.7 24.9 ± 5.6 30.4 ± 5.03 0.011
Qa (g N/12 h) 40.2 ± 11.0 31.5 ± 6.1 37.5 ± 8.6 33.6 ± 10.7 0.166
Qu/Qa 0.70 ± 0.21 0.72 ± 0.17 0.70 ± 0.29 1.0 ± 0.36 0.063
Q(g/12 h) 207.7 ± 38.0 168.1 ± 26.34 194.8 ± 27.1 200.1 ± 27.2 0.033
Q(g·kg body wt 1·12 h 1) 3.47 ± 0.83 2.66 ± 0.33 3.92 ± 0.883 4.02 ± 0.973 0.002
Q(g·kg LBM 1·12 h 1) 4.75 ± 0.97 3.53 ± 0.404 4.89 ± 0.913 4.97 ± 1.113 0.002
Protein synthesis
(g/12 h 1) 169.7 ± 36.4 136.4 ± 21.5 164.9 ± 31.4 147.3 ± 38.9 0.093
(g·kg body wt 1·12 h 1) 2.84 ± 0.76 2.16 ± 0.27 3.33 ± 0.933 2.97 ± 1.05 0.019
(g·kg LBM 1·12 h 1) 3.88 ± 0.92 2.86 ± 0.34 4.15 ± 1.003 3.69 ± 1.29 0.023
Protein degradation
(g/12 h 1) 146.6 ± 39.7 105.1 ± 24.24 144.1 ± 30.5 149.1 ± 28.3 0.011
(g·kg body wt 1·12 h 1) 2.47 ± 0.83 1.66 ± 0.33 2.92 ± 0.883 3.02 ± 0.973 0.002
(g·kg LBM 1·12 h 1) 3.37 ± 1.02 2.20 ± 0.414 3.63 ± 0.953 3.73 ± 1.113 0.002
Protein intake, excretion, and balance
Intake (g·kg LBM 1·12 h 1) 1.39 ± 0.11 1.33 ± 0.07 1.31 ± 0.114 1.24 ± 0.104 0.007
Excretion(g·kg LBM 1·12 h 1) 0.87 ± 0.12 0.66 ± 0.11 0.74 ± 0.27 1.28 ± 0.523–5 <0.001
Balance (g·kg LBM 1·12 h 1) 0.52 ± 0.19 0.67 ± 0.13 0.52 ± 0.26  0.04 ± 0.573–5 <0.001
1x – ± SD. All protein metabolism values were calculated from averages of end products and are expressed as grams of protein, except where stated. LBM,
lean body mass measured by dual-energy X-ray absorptiometry; Qu, ﬂux calculated from the urea end product only; Qa, ﬂux calculated from the ammonia
end product only; Q, ﬂux calculated from the average of Qu and Qa; TB, tuberculosis; HIVTB, coinfection with HIV and TB.
2ANOVA with post hoc Scheffe’s test.
3Signiﬁcantly different from the HIV group, P < 0.05.
4Signiﬁcantly different from the control group, P < 0.05.
5Signiﬁcantly different from the TB group, P < 0.05.
TABLE 2
Comparison of habitual energy and protein intakes between the 4 groups1
Group
Control (n = 11) HIV (n = 10) TB (n = 10) HIVTB (n =8 ) P2
Energy
(kcal) 1733 ± 465 1966 ± 270 1616 ± 380 1820 ± 534 0.308
(kcal/kg body wt) 28.6 ± 7.1 31.2 ± 4.3 32.3 ± 9.0 36.6 ± 12.9 0.70
Protein
(g) 63.6 ± 14.5 91.1 ± 19.53 66.0 ± 18.34 69.1 ± 23.4 0.008
(g/kg LBM) 1.5 ± 0.3 1.9 ± 0.4 1.6 ± 0.5 1.7 ± 0.6 0.15
Protein:energy (%) 15.0 ± 2.1 18.5 ± 2.83 15.0 ± 1.84 16.3 ± 2.2 0.004
1x – ± SD. LBM, lean body mass measured by dual-energy X-ray absorptiometry. TB, tuberculosis; HIVTB, coinfection with HIV and TB.
2ANOVA with post hoc Scheffe’s test.
3Signiﬁcantly different from the control group, P < 0.05.
4Signiﬁcantly different from the HIV group, P < 0.05.
net balance were not significantly different from the control
group. Rates of protein flux, synthesis, degradation, and net bal-
ance were not significantly different between the TB and control
groups. The HIVTB group had values of protein flux, synthe-
sis, and degradation that were not significantly different from
those of the control group. However, the net protein balance was
significantly lower in the HIVTB group than in the control
group and was close to zero. There was no significant correla-
tion in either the TB or HIVTB group between the duration of
TB treatment before the study and any of the protein metabo-
lism variables.
The ratio of urea flux to ammonia flux did not differ signifi-
cantly between the HIV, TB, and control groups but showed a
trend to higher values in the HIVTB group than in the other groups
(P = 0.063 for between-group difference). There was no signifi-
cant correlation between the ratio of urea to ammonia flux and the
ratio of visceral to appendicular lean tissue mass (r = 0.157).
DISCUSSION
In the current study we found that whole-body protein flux and
protein degradation were significantly lower in the HIV-infected
patients than in the other 3 groups. Because the HIV patients
reported a good dietary intake and were not wasted, it is likely that
the difference was due to a direct effect of HIV infection on pro-
tein homeostasis. The near normal values of protein flux in the
HIVTB group indicate that the down-regulation of protein
turnover can be reversed when there is sufficient inflammatory
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stimulus, which suggests that the block is not absolute but more
likely represents a selective response to some feature of the
chronic infection.
It is likely that the protein kinetic response to any infection will
vary with dietary intake, body composition, nutritional-metabolic
state, and intensity of the response to the infective agent. The var-
ied findings in previous studies of protein turnover in HIV-infected
patients may reflect differences in these variables or differences in
standardization approaches. When oral [15N]glycine and the end
product method were used in 9 asymptomatic subjects with AIDS,
whole-body protein flux was reduced and there was a reduction
in the fractional synthesis rate for fibrinogen (15). This finding,
together with an inversion in the ratio of plasma essential to
nonessential amino acids, led the authors to argue that the
decrease in protein flux represented a starvation response. A sim-
ilar pattern of change in the present study cannot be explained on
this basis because the HIV patients had a good nutritional intake.
It is also unlikely that the significantly higher ratio of protein to
energy in the diet of the HIV patients (possibly a deliberate mod-
ification that was perceived to be advantageous) explained the
observed down-regulation of protein flux. In contrast with these
results, when the same method was used, whole-body protein flux
was found to be high and variable in a group of AIDS patients who
were receiving an adequate food intake but who were experienc-
ing weight loss (16). The authors report an association between
protein flux and body cell mass as a proportion of body weight,
which raises the possibility that the apparent increase in flux
might be due in part to changes in body composition that were not
fully accounted for when body weight was used as the denomina-
tor (17, 18). The results of protein-turnover studies in HIV-
infected children emphasize the need to standardize for body com-
position (19). The possible differences in the overall rates of
protein metabolism between our group of Asian patients and in
white cohorts from other studies, because of racial differences in
body composition, does not explain the between-group differences
we observed. Initial reports in which [13C]leucine was used to
assess changes in protein metabolism suggest that both protein
synthesis and degradation increased (20). Later studies indicated
that, in wasted patients, muscle protein synthesis might be down-
regulated, even when there is an overall increase in whole-body
synthesis (21, 22) and that the extent of change might be respon-
sive to the level of activity or to nutritional or hormonal modula-
tion (12, 23, 24). In addition to differences in body composition
and nutritional intake, the contrasting results between studies may
also reflect the marked clinical heterogeneity of patients with HIV
disease. Measurements of resting energy expenditure in HIV-
infected patients suggest the occurrence of hypometabolism in
some patients (25, 26) and marked hypermetabolism in others,
which are usually associated with secondary infections (27). The
higher rates of protein flux in the HIVTB than in the HIV group
in this study support the suggestion that protein flux is elevated in
patients with secondary infection and more advanced disease, pos-
sibly reflecting the direct effects of the infection or the effects of
the associated wasting (20).
We found no significant differences in protein metabolism vari-
ables between the TB and control groups. This finding is in gen-
eral agreement with the findings of the only previously published
study of protein metabolism in TB (11). Given the marked inflam-
matory stimulus evoked by TB, the lack of a difference may
appear somewhat surprising, but the pattern at the whole-body
level may mask more complex alterations in protein metabolic
rates in specific tissues during an active inflammatory process.
Nevertheless, the findings contrast with the observation of a 36%
increase in protein flux in patients with melioidosis (a chronic bac-
terial infection similar to TB) (28) and with the increased flux doc-
umented in patients with surgical sepsis (29, 30), measles (31),
and malaria (32). It may be that the degree of malnutrition offset
the stimulus of TB on protein metabolism in our patients (31) or
that our patients had a particularly effective adaptive response of
protein metabolism to the chronic inflammatory state (28, 33). The
TB patients achieved a state of net anabolism during feeding that
is consistent with the results of studies of nitrogen balance in TB
patients (34), the results of a previous study of protein metabo-
lism in TB patients (ie, a blunted but still strongly anabolic
response) (11), and the results of studies in other chronic infec-
tions (20, 28). Taken together, the evidence supports the idea that
patients with TB should be fed to achieve net protein accretion.
The patients with concomitant HIV and TB infections (HIVTB
group) had protein flux rates that were not significantly different
from those of the control group. However, although net protein
balance varied widely in the HIVTB group (probably reflecting
the greater clinical heterogeneity of the patients in this group), net
anabolism was significantly lower in the HIVTB group than in all
other groups. The absence or attenuation of net anabolism in fed
patients is consistent with studies in patients with acute severe
infections such as malaria and surgical sepsis and in HIV patients
with opportunistic infections (12, 29, 30, 32) but contrasts with
the findings of most studies of chronic infection (11, 20, 28). This
may reflect the fact, which is confirmed by our observations in the
current study, that TB is a more fulminant and disseminated dis-
ease in patients with advanced HIV disease than it is in patients
without HIV infection, who usually have loclaized pulmonary TB.
Thus, in HIV-infected patients, coinfection with TB may evoke a
response that more resembles acute, severe septicemia rather than
a chronic infection. It is worth noting that the HIVTB group had
more advanced HIV disease than did patients in the HIV group, as
evidenced by lower CD4+ counts and higher viral loads. Higher
levels of HIV replication per se may also contribute to the meta-
bolic disturbances that we observed in the HIVTB group. The
absence of net anabolism that we observed may also reflect a fail-
ure of adaptive nitrogen-conserving responses, which are ordi-
narily associated with chronic infection (28, 33). Although the
mechanism of these responses is unknown, they may well be
linked to the maturing immune response to infection. Thus, in the
context of an HIV-induced deficiency of the immune response to
chronic TB, there may be a corresponding deficiency of adaptive
nitrogen-conserving responses. The findings may explain the
marked adverse effect of TB on body cell mass in patients coin-
fected with TB and HIV, which remains even after a period of
effective treatment (2), and indicate that administration of an ana-
bolic agent concomitant with feeding might be of benefit in the
restoration of good nutritional status.
Whole-body protein turnover measurement with the use of
[15N]glycine provides a summary of complex exchange reactions
within the body. However, its application is limited and the basic
assumption that there is a single homogenous metabolic pool of
body protein without compartmentation of processes is of ques-
tionable validity (35). Nevertheless, under standard conditions,
useful information can be obtained with the end product method
(14, 17, 18, 35), and it gives similar results to the alternative
[13C]leucine method (35). Although the concept remains to be val-
idated, it has been suggested that in addition to the use of the end
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product average, calculation of rates based on the individual end
products—either urea or ammonia—might provide an under-
standing of the changes taking place in different compartments of
the body. The ammonia end product may more closely reflect
events in muscle, whereas the urea end product may weight toward
visceral or hepatic activity (13, 36, 37). We found that the patients
in the HIVTB group had a trend toward an elevated ratio of urea
to ammonia flux (P = 0.06); however, in the other 2 groups the
ratio was not significantly different from that of the control group.
This elevated ratio cannot simply be explained by the higher ratio
of visceral to appendicular lean tissue mass in the HIVTB group
because the TB group also had an elevated lean tissue ratio but no
elevated flux ratio.
Furthermore, we did not find a strong correlation between the
flux ratio and the lean tissue ratio, as was observed in previous
studies (17, 18). Therefore, the observed elevation in the ratio of
urea to ammonia may reflect changes in compartmental protein
metabolism induced by infection. The results agree with the find-
ings in rat studies, which showed a decrease in muscle protein syn-
thesis and an increase in liver protein synthesis in response to sep-
sis (38). Although we did not measure changes in the metabolism
of sulfur amino acids in the current study, such changes have been
documented in HIV infection and may modulate the balance of
protein synthesis in liver and muscle (39, 40). Given the world-
wide importance of TB and HIV coinfection and the frequency of
wasting and its adverse effect on prognosis, additional studies are
warranted to further define the metabolic response of protein to
these infections and to investigate ways of restoring the response
toward normality.
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